SCHEMBL4064361

SCHEMBL4064361

COC(=O)Cc1c(C#N)c(OC)nc(C)c1-c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SQOR Q9Y6N5 6/20 0.45
GAA P10253 2/20 0.44
ALDH1A1 P00352 5/20 0.44
HTT P42858 2/20 0.44
HSD17B10 Q99714 2/20 0.44
KDM4E B2RXH2 4/20 0.43
L3MBTL1 Q9Y468 4/20 0.43
USP2 O75604 2/20 0.43
TDP1 Q9NUW8 2/20 0.42
CYP1A2 P05177 1/20 0.42
THRB P10828 1/20 0.42
BLM P54132 1/20 0.42
HPGD P15428 3/20 0.41
NPSR1 Q6W5P4 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MEN1 O00255 1/20 0.40
POLB P06746 1/20 0.40
MAPT P10636 1/20 0.40
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4475072 0.82 SQOR (0.51) SQORGAAALDH1A1HTTHSD17B10
SCHEMBL4072588 0.77 SQOR (0.56) SQORGAAALDH1A1HTTHSD17B10
SCHEMBL4075279 0.75 SQOR (0.62) SQORGAAALDH1A1HSD17B10KDM4E
SCHEMBL4069859 0.71 SQOR (0.50) SQORALDH1A1HTTHSD17B10KDM4E
SCHEMBL4070845 0.71 SQOR (0.49) SQORGAAALDH1A1HTTHSD17B10
SCHEMBL7020462 0.71 SQOR (0.48) SQORGAAALDH1A1HTTHSD17B10
SCHEMBL4073517 0.69 ADORA1 (0.48) SQORGAAALDH1A1KDM4EL3MBTL1
SCHEMBL7022233 0.69 SQOR (0.57) SQORGAAALDH1A1HTTHSD17B10
SCHEMBL4070239 0.69 HSD17B10 (0.46) GAAALDH1A1HTTHSD17B10KDM4E
SCHEMBL7015266 0.68 SQOR (0.55) SQORALDH1A1HSD17B10KDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7601736-B2 Such as 3,4-dihydro-pyrano[3,4-c]pyridine-1-on; cytokine suppressive antiinflammatory drugs; analgesics SK CHEMICALS CO., LTD. (KR) 2009-10-13 US disclosed
EP-1706412-A4 NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME SK CHEMICALS CO LTD (KR) 2009-03-18 EP disclosed
US-20070254909-A1 Novel Pyridine Derivatives, a Process for Their Preparation and a Pharmaceutical Composition Containing the Same SK CHEMICALS CO., LTD. (KR) 2007-11-01 US disclosed
EP-1706412-A1 NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME SK Chemicals, Co., Ltd. (KR) 2006-10-04 EP disclosed
WO-2005063768-A1 NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME SK CHEMICALS, CO., LTD. (KR) 2005-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254909-A1 Novel Pyridine Derivatives, a Process for Their Preparation and a Pharmaceutical Composition Containing the Same IL5, IL1B, P2RY4 SQOR 264/4885GAA 3796/4885ALDH1A1 1008/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.